Skip to main content

and
  1. No Access

    Chapter and Conference Paper

    High-dose chemotherapy with hematologic rescue for high-risk non-seminomatous germ cell tumors

    Despite progress in the treatment of disseminated non-seminomatous germ cell tumors (NSGCT), 20–30%of patients do not achieve CR or relapse [1]. We evaluated high-dose chemotherapy (HDC) followed by autologous...

    J. L. Pico, J. P. Droz, E. Zambon in Proceedings of the 3rd International Congr… (1991)

  2. No Access

    Chapter and Conference Paper

    No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors

    The results of the treatment of non-seminomatous germ cell tumors (NSGCT) have been dramatically improved by Cisplatin-based chemotherapy regimens and selective indication of surgery. Approximately 80 % of all...

    H. Curé, J. P. Droz, J. L. Pico, P. Biron, P. Kerbrat in Cancer Treatment An Update (1994)